Get the latest Zacks research report on BPMC - FREE. ![]() This article used data provided by Zacks Investment Research via. Currently, there are 59. During the last market session, Blueprint Medicines Corp’s stock traded between 44.23 and 45.96. Blueprint Medicines Corp is down 5.21 from its previous closing price of 44.52. The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. As of April 04, 2023, 4:00 PM CST, Blueprint Medicines Corp’s stock price was 42.20. And so with BPMC crossing above that average target price of $103.25/share, investors in BPMC have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $103.25 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Blueprint Medicines Corp: by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients.But the whole reason to look at the average BPMC price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. ![]() Pharmaceutical Preparation Manufacturingīlueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. The 17 analysts offering 12-month price forecasts for Blueprint Medicines Corp have a median target of 82.00, with a high estimate of.Industry Pharmaceutical Preparation Manufacturing.For more information, visit follow us on and LinkedIn. In addition, we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy. Today, we are delivering our approved medicines to patients in the United States, Europe, and in other geographies ourselves or through our partners. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. The options and RSUs are subject to the terms and conditions of Blueprint Medicines' 2020 Inducement Plan, and the terms and conditions of the stock option and RSU agreement covering the grant.īlueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. ![]() Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to each such employee's continued employment on each vesting date. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 1/48th of the shares underlying the option monthly thereafter, in each case, subject to each such employee's continued employment on each vesting date. The options have an exercise price of $48.24 per share, which is equal to the closing price of Blueprint Medicines' common stock on November 1, 2022. ![]() The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Blueprint Medicines, as an inducement material to such individual's entering into employment with Blueprint Medicines, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |